 |
English | deutsch | Impressum | ||
| Sitemap | Disclaimer |
 |
 |
 |
 |
 |
 |
 |
|
Pipeline |
CA IX Antigen – A Highly Specific Tumour Target RENCAREX® (WX-G250) binds specifically to the protein carbonic anhydrase IX (CA IX, MN, or G250 antigen). CA IX is expressed on the cell surface in over 90% of all clear cell RCC, but not expressed in normal kidney tissue. The antigen is also present in bladder cancer and a variety of other solid tumours, including cervical, colon, breast, and non-small cell lung cancer. The antigen is expressed at low levels in the gastric epithelium, upper intestinal tract epithelium, and the bile ducts, but is undetected in normal kidney and other tissues. |
|
 Fig.: IHC Staining Illustration of RCC and healthy kidney tissue shows the high specifity of the antibody. The antibody does not bind to normal kidney tissue (greyish area, lower right) but stains specifically only renal cell cancer (brownish area, upper left). |
||
Mode of Action of RENCAREX®– ADCC The WX-G250 antibody binds to the CA IX antigen
expressed on the tumour cells, thereby triggering an immune reaction
called Antibody-Dependent Cellular Cytotoxicity (ADCC). Through this
mechanism,
effector cells, e.g. NK (natural killer) cells, of the immune system
are activated
to kill the tumour cells.  Fig.: ADCC mechanism of action. The variable region of the WX-G250 antibody binds to CA IX expressed on the tumour cells. The constant region of WX-G250 binds to the Fc receptor of natural killer cells (NK cells). NK cells act as effector cells, which destroy the tumour cells.
|
 |
|
| © 2006 WILEX AG |
Overview
Therapeutic Target